Piramal Pharma Solutions plans expansion in Scotland
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
PEL will explore the PLI scheme and apply if its beneficial.
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
Dr. Muthu was last associated with Mankind Pharma
Subscribe To Our Newsletter & Stay Updated